Last reviewed · How we verify

NCT05510011

Allograft and Tantalum Cone Reconstruction in TKA Revision

Status unknown Last updated 22 August 2022
What this trial tests

trial in Tantalum in 76 participants. Status unknown.

Timeline
1 January 2022
Primary endpoint
20 February 2023
21 February 2023

Quick facts

Lead sponsorUniversity Hospital, Montpellier
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment76
Start date1 January 2022
Primary completion20 February 2023
Estimated completion21 February 2023
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

18 and older, any sex, with Tantalum or Bone Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A new surgical technique of reconstruction for bone loss in TKA revision using tantalum cone and allograft. Study of radiological and clinical outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05510011.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing